GILLETTE CHILDRENS SPECIALTY HEALTH
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $1.1M
- Transactions
- 170
- Companies
- 28
- Average per transaction
- $6,599
Who reported the payments
| Biogen | $518,087 |
| Acadia Pharmaceuticals Inc | $224,723 |
| Mallinckrodt Hospital Products Inc. | $83,940 |
| Mallinckrodt Enterprises LLC | $60,780 |
| Genentech, Inc. | $52,563 |
| Ipsen Biopharmaceuticals, Inc | $30,900 |
| Teva Pharmaceuticals USA, Inc. | $23,500 |
| Stryker | $22,736 |
| Amgen | $22,589 |
| Ultragenyx Pharmaceutical Inc. | $13,514 |
| PTC Therapeutics, Inc. | $12,350 |
| Novartis | $10,450 |
| Sarepta Therapeutics, Inc. | $9,340 |
| UCB Biosciences Inc. | $8,742 |
| Medline Industries LP | $6,387 |
| AbbVie | $5,604 |
| Medtronic | $5,000 |
| GW Research Limited | $3,041 |
| AstraZeneca | $2,000 |
| Medical Device Business Services, Inc. | $2,000 |
| Jazz Pharmaceuticals Inc. | $2,000 |
| Medical Graphics Corporation | $650 |
| Kls-martin L.p. | $330 |
| Ipsen Innovation | $250 |
| Johnson & Johnson | $192 |
| Boston Scientific | $100 |
| KARL Storz Endoscopy-america | $54 |
| Baxter Healthcare | $35 |